BonesLabsBlog
Back to all posts
Uncategorized

Sermorelin

Sermorelin: A GHRH(1–29) Analogue Used in Growth Hormone Research

Research summary. Sermorelin is a synthetic peptide corresponding to the first 29 amino acid residues of human growth hormone-releasing hormone (GHRH), the bioactive N-terminal fragment that retains full receptor-activating activity. It was historically marketed in the United States as Geref for the diagnostic evaluation of pituitary growth hormone reserve and for short-stature paediatric indications, before commercial withdrawal. Sermorelin is now used primarily as a research and compounded-pharmacy GHRH agonist, often paired in research protocols with growth-hormone-releasing peptides (GHRPs) such as ipamorelin or hexarelin to leverage the synergistic dual-pathway pulse on pituitary GH release.

Molecular profile

  • Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (GHRH residues 1–29, C-terminal amide)
  • Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S
  • Molecular weight: ~3357.9 g/mol
  • PubChem CID: 16129620
  • Class: GHRH receptor agonist (truncated GHRH analogue)
  • Synonyms: GHRH(1–29); Geref (historical brand)

Mechanism of action

Sermorelin engages the GHRH receptor on pituitary somatotrophs through the same binding-and-activation mechanism as endogenous full-length (1–44) GHRH:

  • GHRH receptor agonism. Binds the GHRH receptor (a class B GPCR), triggering Gαs-mediated cAMP elevation, which drives both immediate GH release from secretory granules and longer-term increases in GH gene transcription.
  • Pulsatile GH release pattern. Because Sermorelin acts through the physiological GHRH-receptor pathway, the resulting GH release retains pulsatility and is subject to negative feedback from circulating IGF-1 and somatostatin tone — preserving the homeostatic architecture in a way that exogenous recombinant human GH does not.
  • Synergy with GHRPs. When co-administered with a ghrelin-mimetic / GHS-R1a agonist (ipamorelin, hexarelin, GHRP-2), the resulting GH pulse is substantially larger than the sum of individual contributions, reflecting the dual-receptor-pathway architecture of pituitary GH release.

The pulsatility-preserving mechanism is the central pharmacological argument for GHRH-axis modulation as an alternative to direct recombinant GH administration in research contexts.

Preclinical and clinical research highlights

GH-reserve diagnostic use. The historical clinical role of Sermorelin (as Geref) was as a provocative test of pituitary GH reserve, exploiting its ability to rapidly stimulate maximal GH release from a functioning somatotroph population.

Paediatric short-stature trials. Sermorelin was studied in idiopathic short-stature populations and reported to support catch-up growth in some clinical trials. Commercial withdrawal in the U.S. was a business decision rather than a safety- or efficacy-driven action.

Adult GH-axis research. Sermorelin has been used in research investigating age-related declines in GH and IGF-1 axis activity, with reported increases in pulsatile GH release and IGF-1 in adult research subjects.

GHRH-GHRP combination work. Combination protocols with ipamorelin or other GHRPs have been described in research literature, supporting the dual-pathway-synergy hypothesis.

Current research status

Sermorelin is not currently FDA-approved in the U.S. as a commercially marketed drug, following the withdrawal of Geref. It remains available through compounding pharmacies under prescription and as a research-grade peptide for laboratory use.

The combination of "Sermorelin + ipamorelin" or similar GHRH/GHRP blends is a common research configuration; researchers should refer to the individual peptide entries for mechanism and evidence-base details on each component.

For research-supplier contexts, Sermorelin is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

  • Sermorelin is the synthetic GHRH(1–29) fragment, retaining full GHRH-receptor agonist activity.
  • It acts via the physiological GHRH-receptor pathway, preserving pulsatile GH release and IGF-1 negative feedback in a way exogenous GH does not.
  • It was historically FDA-approved as Geref for GH-reserve diagnostic testing and short-stature indications, before commercial withdrawal.
  • Research interest centres on GH-axis modulation, age-related GH-axis decline, and GHRH-GHRP combination protocols.
  • Sermorelin is not currently a commercially marketed FDA-approved drug; research-grade material is for laboratory use only.

References

  1. Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO. Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. J Clin Endocrinol Metab. 1987;64(6):1136–1141.
  2. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.

This article is provided for educational and research purposes only. Sermorelin is a research peptide. It is not currently a commercially marketed FDA-approved drug and is not intended for human consumption outside of a regulated prescription channel. It is not intended for diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

Sermorelin | BonesLabs